BridgeBio Pharma (BBIO) News Today $26.18 -0.77 (-2.86%) (As of 09/13/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 Time Period September 15 at 3:30 AM | marketbeat.comVictory Capital Management Inc. Has $9.69 Million Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Victory Capital Management Inc. raised its stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 9.9% in the second quarter, according to its most recent 13F filing with the SEC. The fund owned 382,717 shares of the company's stock after purchasing an additional 34,360 shares durSeptember 14 at 1:19 AM | americanbankingnews.comLeerink Partnrs Brokers Raise Earnings Estimates for BridgeBio Pharma, Inc. (NASDAQ:BBIO)September 13 at 2:58 PM | marketbeat.comBridgeBio Pharma (NASDAQ:BBIO) Shares Down 2.2% BridgeBio Pharma (NASDAQ:BBIO) Stock Price Down 2.2%September 13 at 6:21 AM | marketbeat.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) to Post Q3 2024 Earnings of ($0.85) Per Share, Leerink Partnrs ForecastsBridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) - Equities researchers at Leerink Partnrs boosted their Q3 2024 earnings per share (EPS) estimates for BridgeBio Pharma in a report issued on Tuesday, September 10th. Leerink Partnrs analyst M. Foroohar now forecasts that the company will post eaSeptember 13 at 6:18 AM | markets.businessinsider.comStrategic Refocusing and Financial Prudence Bolster BridgeBio Pharma’s Long-term Outlook: Maintaining a Buy RatingSeptember 13 at 2:09 AM | americanbankingnews.comBank of America Reiterates "Buy" Rating for BridgeBio Pharma (NASDAQ:BBIO)September 11, 2024 | markets.businessinsider.comBuy Rating Affirmed for BridgeBio Pharma Amid Promising Clinical Trials and Strategic DecisionsSeptember 11, 2024 | marketbeat.comBridgeBio Pharma (NASDAQ:BBIO) Shares Gap Down to $29.99BridgeBio Pharma (NASDAQ:BBIO) Shares Gap Down to $29.99September 11, 2024 | marketbeat.comBridgeBio Pharma (NASDAQ:BBIO) Given Buy Rating at Bank of AmericaBank of America restated a "buy" rating and issued a $42.00 price objective on shares of BridgeBio Pharma in a research report on Wednesday.September 10, 2024 | reuters.comBridgeBio to stop development of therapy for genetic disorderSeptember 10, 2024 | globenewswire.comBridgeBio Receives FDA's Regenerative Medicine Advanced Therapy (RMAT) Designation for BBP-812 Canavan Disease Gene Therapy ProgramSeptember 10, 2024 | globenewswire.comBridgeBio Pharma Reports Topline Results from Phase 1/2 Trial of Investigational Gene Therapy for Congenital Adrenal Hyperplasia (CAH)September 10, 2024 | americanbankingnews.comBridgeBio Pharma's (BBIO) "Overweight" Rating Reaffirmed at Cantor FitzgeraldSeptember 9, 2024 | marketbeat.comBridgeBio Pharma (NASDAQ:BBIO) Receives Overweight Rating from Cantor FitzgeraldCantor Fitzgerald reaffirmed an "overweight" rating and set a $70.00 price target on shares of BridgeBio Pharma in a report on Monday.September 8, 2024 | marketbeat.comEmerald Advisers LLC Decreases Stock Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Emerald Advisers LLC lowered its position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 4.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 666,344 shares of the cSeptember 6, 2024 | globenewswire.comBridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)September 6, 2024 | americanbankingnews.comBridgeBio Pharma (NASDAQ:BBIO) Earns Overweight Rating from Analysts at Piper SandlerSeptember 5, 2024 | msn.comPiper Sandler Initiates Coverage of BridgeBio Pharma (BBIO) with Overweight RecommendationSeptember 5, 2024 | seekingalpha.comBridgeBio draws bullish view at Piper on potential acoramidis nodSeptember 5, 2024 | americanbankingnews.comBridgeBio Pharma (NASDAQ:BBIO) Rating Reiterated by HC WainwrightSeptember 4, 2024 | marketbeat.comBridgeBio Pharma (NASDAQ:BBIO) Trading Up 4.8%BridgeBio Pharma (NASDAQ:BBIO) Trading 4.8% HigherSeptember 4, 2024 | marketbeat.comBridgeBio Pharma (NASDAQ:BBIO) Research Coverage Started at Piper SandlerPiper Sandler began coverage on shares of BridgeBio Pharma in a research report on Wednesday. They set an "overweight" rating and a $46.00 price target for the company.September 4, 2024 | markets.businessinsider.comEvercore ISI Reaffirms Their Buy Rating on BridgeBio Pharma (BBIO)September 4, 2024 | markets.businessinsider.comBuy Rating Affirmed for BridgeBio Pharma on Acoramidis’s Promising Treatment Efficacy and Best-in-Class PotentialSeptember 3, 2024 | marketbeat.comBridgeBio Pharma (NASDAQ:BBIO) Sees Strong Trading VolumeBridgeBio Pharma (NASDAQ:BBIO) Sees Large Volume IncreaseSeptember 3, 2024 | marketbeat.comHC Wainwright Reaffirms "Buy" Rating for BridgeBio Pharma (NASDAQ:BBIO)HC Wainwright reissued a "buy" rating and issued a $43.00 target price on shares of BridgeBio Pharma in a research note on Tuesday.September 2, 2024 | marketbeat.comPrincipal Financial Group Inc. Boosts Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Principal Financial Group Inc. lifted its stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 4.8% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,125,145 shares of the companSeptember 1, 2024 | marketbeat.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Short Interest UpdateBridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) saw a large decline in short interest during the month of August. As of August 15th, there was short interest totalling 18,020,000 shares, a decline of 9.7% from the July 31st total of 19,960,000 shares. Based on an average daily volume of 1,820,000 shares, the days-to-cover ratio is presently 9.9 days. Currently, 12.8% of the company's stock are sold short.August 31, 2024 | markets.businessinsider.comBuy Rating Affirmed for BridgeBio Pharma Amidst ATTR-CM Treatment Market DynamicsAugust 31, 2024 | msn.comWhy Is BridgeBio Pharma Stock Trading Higher On Friday?August 31, 2024 | businesswire.comBRIDGEBIO PHARMA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates BridgeBio Pharma, Inc. - BBIOAugust 31, 2024 | seekingalpha.comBridgeBio: With HELIOS-B Overhang Removed, Focus To Turn To Approval And Launch Of AcoramidisAugust 30, 2024 | marketbeat.comBridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares Purchased by Panagora Asset Management Inc.Panagora Asset Management Inc. lifted its holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 75.3% during the second quarter, according to the company in its most recent filing with the SEC. The fund owned 727,963 shares of the company's stock after buying an additional 312,686 shareAugust 30, 2024 | marketbeat.comBridgeBio Pharma (NASDAQ:BBIO) Shares Gap Up to $24.62BridgeBio Pharma (NASDAQ:BBIO) Shares Gap Up to $24.62August 30, 2024 | in.investing.comAinylam Pharmaceuticals shares tumble following study results, BridgeBio Pharma risesAugust 30, 2024 | markets.businessinsider.comOptimistic Outlook for BridgeBio Pharma with Acoramidis Leading Market Share ProjectionsAugust 29, 2024 | ca.finance.yahoo.comBBIO Aug 2024 23.500 putAugust 29, 2024 | globenewswire.comBridgeBio to Present Additional Analyses from the Phase 3 ATTRibute-CM Trial of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the ESC Congress 2024 and the HFSA Annual Meeting 2024August 28, 2024 | globenewswire.comBridgeBio Pharma to Participate in September Investor EventsAugust 27, 2024 | markets.businessinsider.comBridgeBio Pharma: Strategic Collaborations and Promising Pipeline Bolster Buy RatingAugust 26, 2024 | globenewswire.comBridgeBio Partners with Leading Cardiovascular Data Science Lab (CarDS Lab) to Improve Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Diagnosis in Diverse Patient Populations with Multimodal Artificial IntelligenceAugust 22, 2024 | markets.businessinsider.comPositive Buy Rating for BridgeBio Pharma Backed by Strategic Initiatives and Upcoming CatalystsAugust 22, 2024 | seekingalpha.comBridgeBio: PDUFA Date Expected In November 2024 Could Shift MomentumAugust 22, 2024 | bizjournals.comBridgeBio gathers investors to launch rare disease-focused spinoffAugust 22, 2024 | marketbeat.comBridgeBio Pharma's (BBIO) Buy Rating Reiterated at HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $43.00 price objective on shares of BridgeBio Pharma in a research note on Thursday.August 21, 2024 | insidertrades.comBrian C. Stephenson Sells 4,155 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) StockAugust 21, 2024 | insidertrades.comInsider Selling: BridgeBio Pharma, Inc. (NASDAQ:BBIO) CEO Sells 27,389 Shares of StockAugust 20, 2024 | marketbeat.comHennion & Walsh Asset Management Inc. Sells 104,995 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO)Hennion & Walsh Asset Management Inc. lowered its position in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 72.9% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 39,099 shares of the company's stock after seAugust 19, 2024 | globenewswire.comBridgeBio Launches MyAchonJourney, a New Resource for Families Navigating AchondroplasiaAugust 19, 2024 | marketbeat.comAssenagon Asset Management S.A. Boosts Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO)Assenagon Asset Management S.A. boosted its position in BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 3,429.6% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 246,895 shares of the company's stock after purchasing an additional 239,900 share Get BridgeBio Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for BBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address Kamala’s Dirty Election Move… Revealed (Ad)According to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… Click here now and learn how to prepare. BBIO Media Mentions By Week BBIO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BBIO News Sentiment▼0.510.71▲Average Medical News Sentiment BBIO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BBIO Articles This Week▼216▲BBIO Articles Average Week Get BridgeBio Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for BBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Perrigo News Amicus Therapeutics News Arrowhead Pharmaceuticals News Schrödinger News Allakos News United Therapeutics News Teva Pharmaceutical Industries News BeiGene News Genmab A/S News Summit Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BBIO) was last updated on 9/15/2024 by MarketBeat.com Staff From Our PartnersInvest before this deal closes on 9/18This company can create aviation fuels from waste, they qualify to help airlines meet net-zero carbon pledges ...Deal Maker | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredWar on Elon Escalates… A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | SponsoredKamala Harris and The Woke Progressive NightmareNew research from Jim Rickards - former advisor to the CIA - reveals shocking predictions about an “Election M...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredWhy Institutions Are Bullish on BitcoinThe recent dip in the crypto market might be stressful… But it also presents a tremendous opportunity for s...Crypto 101 Media | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BridgeBio Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BridgeBio Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
